World News: 03:05 GMT Wednesday 15th May 2019. [Yahoo Business News Feed via SPi World News]
The Swiss drugmaker aims to use the one-time personalized therapy in Japan for children and young people with acute lymphoblastic leukemia (ALL) and adult patients with diffuse large B-cell lymphoma (DLBCL). Novartis expects peak annual sales of 7.2 billion yen ($65.7 million) in Japan with up to 216 possible patients, according to a document submitted to the panel. Kymriah works by removing disease fighting T-cells from individual patients, modifying them to attack cancer, and then re-infusing them back into the patients.
SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 07519380.